Invest In Biomed is a unique Eurobiomed program that assists innovative health companies in consolidating their fundraising approach and tools, and connects them with specialized investors in the sector. On the occasion of the launch of the 10th edition of this program, we are featuring entrepreneurs who have benefited from it.
Arnaud Debains and Sandrine Isz are respectively Chief Financial Officer and Chief Science Officer of BOYDSense, a young company developing innovative respiratory analysis technology, enabling patients to easily monitor their health status and manage chronic conditions, particularly diabetes. A laureate of Eurobiomed's Invest In Biomed program in 2023, BOYDSense successfully completed a fundraising round in April 2024.
What motivated you to join the Invest In Biomed program?
Arnaud Debains: After developing our technology, we realized it was challenging to attract investors' attention without prior refinement of our communication strategy.
This is a delicate exercise: one must share sufficient information to generate interest while safeguarding proprietary industrial secrets. The program assisted us in finding this balance, enhancing our narrative, and overcoming our initial reticence, as we possessed significant achievements worthy of promotion.
How did the program assist you in structuring your pitch deck?
Sandrine Isz: The work on our pitch deck proved particularly valuable. Following Eurobiomed's guidance, we notably incorporated a fundamental slide detailing the technical and scientific aspects of our innovation.
Although initially hesitant due to concerns about over-disclosure, this slide has become a pivotal element that we continue to utilize in all our presentations today. It effectively reassures investors regarding the technological robustness of our project.
What did the pitch sessions with investors provide you?
Arnaud Debains: These sessions were beneficial, even though the investors present did not directly participate in our April 2024 fundraising round, which was completed with investors specializing in diabetes and supported by a Horizon 2020 grant.
During the Invest In Biomed pitch sessions, we established lasting contacts with certain investors who continue to monitor our progress. They regularly request updates, and we maintain these relationships, which could prove invaluable for the future. This network is built for the long term.
SIMILAR ARTICLES:
Amaury Ciurana (REEV): “The Invest In Biomed program offered us a privileged framework to build trusting relationships with our investors”
Philippe Andres (Tarian Pharma): 'Invest In Biomed's support enabled us to adapt our communication to investors' expectations.'
